High-Dose Osimertinib in Patients With Advanced-Stage EGFR Exon 20 Mutation–Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Lung Cancer 2022 Jun 23;170(xx)133-140, F Zwierenga, B van Veggel, LEL Hendriks, TJN Hiltermann, BI Hiddinga, LBM Hijmering Kappelle, A Ter Elst, SMS Hashemi, AC Dingemans, C van der Leest, AJ de Langen, MM van den Heuvel, AJ van der WekkenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.